16. 16
ภาคผนวก
National Protocol for Acute Lymphoblastic Leukemia
Protocol name Protocol TPOG- ALL-01-05
Protocol for Low Risk ALL
Open Date 7 May 2005
Patients eligibility
‰ Acute lymphoblastic leukemia
‰ Initial WBC < 50,000/mm3
‰ Age between 1 - 10 yr.
Exclusion criteria
‰ T -cell characteristics; acid phosphatase positive with mediastinal mass,
huge hepatomegaly > 6 cm and/or splenomegaly below the umbilicus
‰ CNS disease at diagnosis
‰ Testicular involvement at diagnosis
‰ Mature B-cell ALL (morphology L3)
Patient’s name Age Sex
Hospital HN BW Ht BSA
Phase I INDUCTION (4 weeks) Date started / /
week 1 2 3 4 5 6
day 1 8 15 22 29 36
Date given
Alkalinization + prophylactic medication + sterile bowel
Prednisolone ___ _________________
Vincristine __ ____ mg IV À À À À
Doxorubicin ___ ___ mg IV Δ Δ
L-asp ___ _______ U IM (M-W-F) I I I I I I
MTX________mg IT* T T
BM aspiration Æ Δ remission Δ not remission „
Drug Dosage Day
Prednisolone 40 mg/m2 /day 1-28 then taper off in 2 wks.
Vincristine 1.5 mg/m2 IV push 1, 8, 15, 22
Doxorubicin 25 mg/m2 IV push 1, 8
L-asparaginase 6,000-10,000 unit /m2 IM M-W-F 8, 10, 12, 15, 17, 19
MTX IT* age adjusted dose intrathecal 1, 15
Prophylactic drugs & Sterile Bowel
ƒ Sodamint 1 tab PO BID (<5yr) or TID (>5yr) First 2 weeks
ƒ Allopurinol (100 mg) 10 mg/kg/day divided BID-QID First 2 weeks
ƒ Clotrimazole troche (10 mg)
or nystatin suspension
1 tab PO TID (>5yr) or
nystatin 2 ml PO QID (<5yr) 1-28
1-1.9 yrs 2-2.9 yrs >3 yrs
* age adjusted dose intrathecal chemotherapy for Methotrexate
8 10 12
กุมภาพันธ์ 2549 แนวทางเวชปฏิบัติ : มะเร็งเม็ดเลือดขาวในเด็ก
17. 17
Patient’s name Age Sex
Hospital HN BW Ht BSA
Protocol TPOG- ALL-01-05
Phase II CONSOLIDATION & CNS PROPHYLAXIS (7 weeks) Date started / /
week 1 2 3 4 5 6 7 8
day 1 8 15 22 29 36 43 50
Date given
6-MP(50 mg) ___ tab q hs
Methotrexate mg IV drip 24 hr À À À À
Hydration & alkalinization¶
Leucovorin tab IV or po q 6 hr X 6 doses
„
Δ
„
Δ
„
Δ
MTX mg* T T T T
¶ See high dose MTX guideline
Drug Dosage Day
Methotrexate 1.5 gm /m2 IV drip in 24 hr
(see Appendix)
1, 15, 29, 43
Leucovorin (start at 12 hr after stop MTX) 15 mg/m2 IV or PO q 6 hr x 6 doses 2, 16, 30, 44
MTX IT* age adjusted dose intrathecal 1, 15, 29, 43
6-MP (50mg) 50 mg /m2 / day PO q hs 1-56
„
Δ
1-1.9 yrs 2-2.9 yrs >3 yrs
* age adjusted dose intrathecal chemotherapy for Methotrexate
8 10 12
Phase III INTERIM - MAINTENANCE PHASE (3 months)
Date started week1 / / , week 5 / / , week 9 / / .
week 1 2 3 4 5 6 7 8 9 10 11 12
Vincristine _____ mg IV À À À
Pred (5 mg) ____________ P P P
MTX (2.5 mg) ___ tab wkly M M M M M M M M M M M M
6-MP(50 mg) ___ tab q hs
Pulse Treatment q 4 weeks Maintenance Dosage
Vincristine 1.5 mg/m2 IV day 1 6-MP (50mg) 50 mg /m2 / day PO q hs
Prednisolone 40 mg/m2 day PO x 5 days Methotrexate (MTX) 20 mg /m2 / week PO
Cotrimoxazole ( ) 5 mg/kg/day PO bid 2-3 day/wk
กุมภาพันธ์ 2549 แนวทางเวชปฏิบัติ : มะเร็งเม็ดเลือดขาวในเด็ก
18. 18
Patient’s name Age Sex
Hospital HN BW Ht BSA
Protocol TPOG- ALL-01-05
Phase IV DELAYED - INTENSIFICATION (7 weeks) Date started / / _
week 1 2 3 4 5 6 7
day 1 8 15 22 29 36 43
Date given
Dexamethasone ___________
Day 1-21
Vincristine ______ mg IV À À À
Doxorubicin ______ mg IV Δ
L-asp ______ U IM
I I I I
Ara-C _______mg IV I I I I I I I I
CTX _______mg IV ‹
6-MP _________________
MTX _______ mg IT* T T
Day 29-42
Drug Dosage Day
Dexamethasone 10 mg/m2 /day PO 1-21 then taper off
Vincristine 1.5 mg/m2 IV push 1, 8, 15
Doxorubicin 25 mg/m2 IV push 1
L-asparaginase 6,000-10,000 unit /m2 IM 8, 11, 15, 18
Cyclophosphamide (CTX) 1,000 mg/m2 IV drip in 1 hr. 29
Cytosine arabinoside (Ara-C) 75 mg/m2 IV push 29-32, 36-39
6-MP (50mg) 50 mg/m2 day PO x 14 days 29-42
MTX IT* age adjusted dose intrathecal 1, 29
1-1.9 yrs 2-2.9 yrs >3 yrs
* age adjusted dose intrathecal chemotherapy for Methotrexate
8 10 12
กุมภาพันธ์ 2549 แนวทางเวชปฏิบัติ : มะเร็งเม็ดเลือดขาวในเด็ก
19. 19
Patient’s name Age Sex
Hospital HN BW Ht BSA
Protocol TPOG- ALL-01-05
Phase V MAINTENANCE Total 2.5 yrs. after remission in girls
Total 3 yrs. after remission in boys
Date remission / / _ Date started maintenance / /
week 1 2 3 4 5 6 7 8 9 10 11 12
MTX _______ mg IT* T
Vincristine ____ mg IV À À À
Pred (5 mg) ____________ P P P
MTX (2.5 mg) ___ tab wkly M M M M M M M M M M M M
6-MP(50 mg) ___ tab q hs
Record date given wk 1 _____________ wk 2 _____________ wk 3 ___________
Ht _____ Wt ______ wk 13 _____________ wk 17_____________ wk 21 ___________
Ht _____ Wt ______ wk 25 _____________ wk 29_____________ wk 33 ___________
Ht _____ Wt ______ wk 37 _____________ wk 41_____________ wk 45 ___________
Ht _____ Wt ______ wk 49 _____________ wk 53_____________ wk 57 ___________
Ht _____ Wt ______ wk 61 _____________ wk 65_____________ wk 69 ___________
Ht _____ Wt ______ wk 73 _____________ wk 77_____________ wk 81 ___________
Ht _____ Wt ______ wk 85 _____________ wk 89_____________ wk 93 ___________
Ht _____ Wt ______ wk 97 _____________ wk 101____________ wk 105 __________
Ht _____ Wt ______ wk 109 ____________ wk 113____________ wk 117 __________
Ht _____ Wt ______ wk 121 ____________ wk 125____________ wk 129 __________
END OF THERAPY Date / / _
Pulse Treatment q 4 weeks Maintenance Dosage
Vincristine 1.5 mg/m2 IV day 1 6-MP (50mg) 50 mg /m2 / day PO q hs
Prednisolone 40 mg/m2 day PO x 5 days Methotrexate (MTX) 20 mg /m2 / week PO
Cotrimoxazole ( ) 5 mg/kg/day PO bid 2-3 day/wk
1-1.9 yrs 2-2.9 yrs >3 yrs
* age adjusted dose intrathecal chemotherapy for Methotrexate
8 10 12
กุมภาพันธ์ 2549 แนวทางเวชปฏิบัติ : มะเร็งเม็ดเลือดขาวในเด็ก
20. 20
Patient’s name Age Sex
Hospital HN BW Ht BSA
Protocol TPOG- ALL-01-05
POST TREATMENT GUIDELINES
Guidelines for follow up patients post treatment
1. 1st year :
ƒ PE, CBC q 2 months.
กุมภาพันธ์ 2549 แนวทางเวชปฏิบัติ : มะเร็งเม็ดเลือดขาวในเด็ก
2. 2nd year :
ƒ PE, CBC q 3 months.
3. 3rd year :
ƒ PE, CBC q 6 months
4. After 3rd year :
ƒ PE, CBC q 12 months
Bone marrow aspiration
1. Before discontinue chemotherapy
2. Unexplained cytopenia
3. Sign & symptom of relapse
Guideline for bactrim prophylaxis
1. Started when consolidation
2. Bactrim is given 5 mg of TMP /kg/day divided bid 2-3 times per week (M-W-F, F-Sa-Su, or Sa-Su)
3. Stop bactrim prophylaxis 1 week before and during CNS prophylaxis with high-dose methotrexate
21. 21
National Protocol for Acute Lymphoblastic Leukemia
Protocol name Protocol TPOG- ALL-02-05
Protocol for High Risk ALL and T-cell NHL or LBL stage III/IV
Open Date 7 May 2005
Patients eligibility
1. Acute lymphoblastic leukemia with any of the following characteristics
‰ Initial WBC > 50,000/mm3
‰ Age > 10 yr or < 1 yr
‰ T -cell characteristics; acid phosphatase +ve with mediastinal mass,
huge hepatomegaly >6 cm and/or splenomegaly below the umbilicus
‰ CNS disease at diagnosis**
‰ Testicular involvement at diagnosis***
2. Non-Hodgkin lymphoma: T-cell or lymphoblastic type, stage III / IV
Exclusion criteria
‰ Mature B-cell ALL
(see SNC protocol)
Patient’s name Age Sex
Hospital HN BW Ht BSA
Phase I INDUCTION (6 weeks) Date started / /
week 1 2 3 4 5 6
day 1 8 15 22 29 36
Date given
Alkalinization + prophylactic medication + sterile bowel
Prednisolone ___ _________________
Vincristine __ ____ mg IV À À À À
Doxorubicin ___ ___ mg IV Δ Δ Δ Δ
L-asp ___ _______ U IM (M-W-F) I I I I I I
MTX________mg IT* T T** T T**
BM aspiration Æ Δ remission Δ not remission „
**CNS disease (positive blast cells in CSF) - add age adjusted dose Triple-T IT weekly until blast cells negative 2 consecutive weeks (at
least 4 doses / maximum 8 doses)
***Testicular involvement - add testicular radiation total dose 1800 cGy.
Drug Dosage Day
Prednisolone 40 mg/m2 /day 1-28 then taper off in 2 wks.
Vincristine 1.5 mg/m2 IV push 1, 8, 15, 22
Doxorubicin 25 mg/m2 IV push 1, 8, 15, 22
L-asparaginase 6,000-10,000 unit /m2 IM M-W-F 8, 10, 12, 15, 17, 19
MTX IT* Age-adjusted dose intrathecally 1, 15
Intrathecal medications 1-1.9 yrs 2-2.9 yrs >3 yrs
*adjust dose according to age MTX 8 10 12
**Triple intrathecal for CNS disease ARA-C 20 25 30
Hydrocortisone 8 10 15
กุมภาพันธ์ 2549 แนวทางเวชปฏิบัติ : มะเร็งเม็ดเลือดขาวในเด็ก
22. 22
Patient’s name Age Sex
Hospital HN BW Ht BSA
Protocol TPOG- ALL-02-05
Phase II CONSOLIDATION (12 weeks) Date started ____/_____/______
week 1 2 3 4 5 6 7 8 9 10 11 12
day 1 8 15 22 29 36 43 50 57 64 71 78
Date given
6-MP _____ tab daily
CTX ________mg IV ‹
Day 1-14 Day 29-85
Ara-C _________mg IV IIII IIII
MTX ______ mg IV drip 24 hr# À# À# À# À#
Hydration & alkalinization¶
Leucovorin____mg q 6hr x 6
„
Δ
„
Δ
„
Δ
„
Δ
MTX _______ mg* T T T T T
#Start MTX IV drip when ANC > 1000 /μL & Plt > 100,000 /μL
¶ See high dose MTX guideline
Drug Dosage Day
6-MP (50mg) 50 mg/m2 day PO 1-14, 29-85
Cyclophosphamide (CTX) 1,000 mg/m2 IV drip in 1 hr. 1
Cytosine arabinoside (Ara-C) 75 mg/m2 IV push 2-5, 8-11
Methotrexate (MTX) 1.5 gm /m2 IV drip in 24 hr 29, 43, 57, 71
Leucovorin (start at 12 hr after stop MTX) 15 mg/m2 IV or PO q 6 hr x 6 doses 30, 44, 58, 72
MTX IT* age adjusted dose intrathecal 1, 29, 43, 57, 71
1-1.9 yrs 2-2.9 yrs >3 yrs
* age adjusted dose intrathecal chemotherapy for Methotrexate
8 10 12
Phase III CNS PROPHYLAXIS# (3 weeks) Date started / /
Cranial radiation (1800 cGy in 10-12 fraction)
Date / / to / /
#Infant leukemia – Postpone CNS prophylaxis until age > 3 year
**Initial CNS involvement - add age adjusted dose Triple-T IT weekly x 2 doses
กุมภาพันธ์ 2549 แนวทางเวชปฏิบัติ : มะเร็งเม็ดเลือดขาวในเด็ก
23. 23
Patient’s name Age Sex
Hospital HN BW Ht BSA
Protocol TPOG- ALL-02-05
Phase IV 1st INTERIM - MAINTENANCE PHASE (12 weeks)
Date started week 1 ____/____/___ week 5 ____/____/___ week 9 ____/____/___
week 1 2 3 4 5 6 7 8 9 10 11 12
Vincristine _____ mg IV À À À
Pred (5 mg) ____________ P P P
MTX (2.5 mg) ___ tab wkly M M M M M M M M M M M M
6-MP(50 mg) ___ tab q hs
Pulse Treatment q 4 weeks Maintenance Dosage
Vincristine 1.5 mg/m2 IV day 1 6-MP (50mg) 50 mg /m2 / day PO q hs
Prednisolone 40 mg/m2 day PO x 5 days Methotrexate (MTX) 20 mg /m2 / week PO
Cotrimoxazole ( ) 5 mg/kg/day PO bid 2-3 day/wk
Phase V 1st DELAYED - INTENSIFICATION PHASE (12 weeks) Date started____/____/___
week 1 2 3 4 5 6
day 1 8 15 22 29 36
Date given
Dexamethasone _________ tab PO
Day 1-21
Vincristine ______ mg IV À À À
Doxorubicin ______ mg IV Δ
L-asp ______ U IM (M- Th)
I I I I
Ara-C _______mg IV I I I I I I I I
CTX _______mg IV ‹
6-MP ______ tab PO
Day 29-42
MTX _______ mg IT* T# T#
Drug Dosage Day
Dexamethasone (0.5 mg tab) 10 mg/m2 /day PO divided tid 1-21 then taper off
Vincristine 1.5 mg/m2 IV push 1, 8, 15
Doxorubicin 25 mg/m2 IV push 1
L-asparaginase (L-asp) 6,000-10,000 unit /m2 IM M- Th 8, 11, 15, 18
Cyclophosphamide (CTX) 1,000 mg/m2 IV drip in 1 hr 29
Cytosine arabinoside (Ara-C) 75 mg/m2 IV push 29-32, 36-39
6-MP (50mg) 50 mg/m2 day PO hs x 14 days 29-42
MTX IT* age adjusted dose intrathecal 1, 29
# Age-adjusted dose triple drug intrathecal in CNS disease until total 10 doses
กุมภาพันธ์ 2549 แนวทางเวชปฏิบัติ : มะเร็งเม็ดเลือดขาวในเด็ก
24. 24
Patient’s name Age Sex
Hospital HN BW Ht BSA
Protocol TPOG- ALL-02-05
Phase VI 2nd INTERIM - MAINTENANCE PHASE (12 weeks)
Date started week 1 ____/____/___ week 5 ____/____/___ week 9 ____/____/___
week 1 2 3 4 5 6 7 8 9 10 11 12
Vincristine _____ mg IV À À À
Pred (5 mg) ____________ P P P
MTX (2.5 mg) ___ tab wkly M M M M M M M M M M M M
6-MP(50 mg) ___ tab q hs
Pulse Treatment q 4 weeks Maintenance Dosage
Vincristine 1.5 mg/m2 IV day 1 6-MP (50mg) 50 mg /m2 / day PO q hs
Prednisolone 40 mg/m2 day PO x 5 days Methotrexate (MTX) 20 mg /m2 / week PO
Cotrimoxazole ( ) 5 mg/kg/day PO bid 2-3 day/wk
Phase VII 2nd DELAYED - INTENSIFICATION PHASE (12 weeks) Date started____/____/___
week 1 2 3 4 5 6
day 1 8 15 22 29 36
Date given
Dexamethasone _________ tab PO
Day 1-21
Vincristine ______ mg IV À À À
Doxorubicin ______ mg IV Δ
L-asp ______ U IM (M- Th)
I I I I
Ara-C _______mg IV I I I I I I I I
CTX _______mg IV ‹
6-MP ______ tab PO
Day 29-42
MTX _______ mg IT* T# T#
Drug Dosage Day
Dexamethasone (0.5 mg tab) 10 mg/m2 /day PO divided tid 1-21 then taper off
Vincristine 1.5 mg/m2 IV push 1, 8, 15
Doxorubicin 25 mg/m2 IV push 1
L-asparaginase (L-asp) 6,000-10,000 unit /m2 IM M- Th 8, 11, 15, 18
Cyclophosphamide (CTX) 1,000 mg/m2 IV drip in 1 hr 29
Cytosine arabinoside (Ara-C) 75 mg/m2 IV push 29-32, 36-39
6-MP (50mg) 50 mg/m2 day PO hs x 14 days 29-42
MTX IT* age adjusted dose intrathecal 1, 29
# Age-adjusted dose triple drug intrathecal in CNS disease until total 10 doses
Patient’s name Age Sex
กุมภาพันธ์ 2549 แนวทางเวชปฏิบัติ : มะเร็งเม็ดเลือดขาวในเด็ก
25. 25
Hospital HN BW Ht BSA
Protocol TPOG- ALL-02-05
Phase VIII MAINTENANCE Total 3 yrs after remission
Date remission / / Date started maintenance / / .
week 1 2 3 4 5 6 7 8 9 10 11 12
MTX _______ mg IT* T
Vincristine ____ mg IV À À À
Pred (5 mg) ____________ P P P
MTX (2.5 mg) ___ tab wkly M M M M M M M M M M M M
6-MP(50 mg) ___ tab q hs
Record date given wk 1 _____________ wk 5 _____________ wk 9 ___________
Ht _____ Wt ______ wk 13 _____________ wk 17_____________ wk 21 ___________
Ht _____ Wt ______ wk 25 _____________ wk 29_____________ wk 33 ___________
Ht _____ Wt ______ wk 37 _____________ wk 41_____________ wk 45 ___________
Ht _____ Wt ______ wk 49 _____________ wk 53_____________ wk 57 ___________
Ht _____ Wt ______ wk 61 _____________ wk 65_____________ wk 69 ___________
Ht _____ Wt ______ wk 73 _____________ wk 77_____________ wk 81 ___________
Ht _____ Wt ______ wk 85 _____________ wk 89_____________ wk 93 ___________
Ht _____ Wt ______ wk 97 _____________ wk 101____________ wk 105 __________
END OF THERAPY Date / / _
Pulse Treatment q 4 weeks Maintenance Dosage
Vincristine 1.5 mg/m2 IV day 1 6-MP (50mg) 50 mg /m2 / day PO q hs
Prednisolone 40 mg/m2 day PO x 5 days Methotrexate (MTX) 20 mg /m2 / week PO
Cotrimoxazole ( ) 5 mg/kg/day PO bid 2-3 day/wk
1-1.9 yrs 2-2.9 yrs >3 yrs
* age adjusted dose intrathecal chemotherapy for Methotrexate
8 10 12
กุมภาพันธ์ 2549 แนวทางเวชปฏิบัติ : มะเร็งเม็ดเลือดขาวในเด็ก
26. 26
Patient’s name Age Sex
Hospital HN BW Ht BSA
Protocol TPOG- ALL-02-05
POST TREATMENT GUIDELINES
Guidelines for follow up patients post treatment
กุมภาพันธ์ 2549 แนวทางเวชปฏิบัติ : มะเร็งเม็ดเลือดขาวในเด็ก
1. 1st year :
• PE, CBC q 2 months.
2. 2nd year :
• PE, CBC q 3 months.
3. 3rd year :
• PE, CBC q 6 months
4. After 3rd year :
• PE, CBC q12 months
Bone marrow aspiration
1. Before stop chemotherapy
2. Unexplained cytopenia
3. Sign & symptom of relapse
Guideline for bactrim prophylaxis
1. Start when consolidation
2. Bactrim is given 5 mg of TMP /kg/day divided bid 2-3 times per week (M-W-F, F-Sa-Su, or Sa-Su)
3. Stop bactrim prophylaxis 1-week before and during CNS prophylaxis with high-dose methotrexate
Reimmunization
-post off treatment 1 yr.
27. 27
National Protocol for Acute Non-Lymphoblastic Leukemia
Protocol name Protocol TPOG-AML-01-05
Modified from Protocol AML-BFM-83: Med Pediatr Onc 1993; 21:8-13
Open Date 15 October 2005
Patients eligibility
Exclusion criteria
‰ Acute non-lymphoblastic leukemia
‰ Relapsed ANLL
Patient’s name Age Sex
Hospital HN BW Ht BSA
Phase I INDUCTION (6 weeks) Date started / /
day 1 2 3 4 5 6 7 8
Date given
Alkalinization + prophylactic medication + sterile bowel
Cytosine Arabinoside _____ mg IV infusion in 24 hr
Cytosine Arabinoside _____ mg IV q 12-24 hr ¿ ¿ ¿ ¿ ¿ ¿
Adriamycin ___ ___ mg IV Δ Δ Δ
Etoposide _______ mg IV drip in I hr ‹ ‹ ‹
MTX____ _ mg* IT T#
BM aspiration when >day 15 and ANC > 1,000 /uL ____/____/____
Results : … in remission (blast < 5%) Æ Phase II consolidation
… Not in remission (blast > 5%) Æ If patient can tolerate chemotherapy, repeat Phase I (date _____ / ____ / _____)
If patient cannot tolerate chemotherapy Æ Phase II consolidation
#CNS disease – MTX IT at week 1; then followed by Ara-C IT weekly until CSF -ve
Drug Dosage Day
Cytosine Arabinoside 100 mg/m2 /day IV infusion in 24 hr 1, 2
Cytosine Arabinoside 50 mg/m2/dose IV q 12-24 hr x 6 days (6-12doses) 3, 4, 5, 6, 7, 8
Adriamycin 25 mg/m2 IV push 3, 4, 5
Etoposide 150 mg / m2 IV drip in 1 hr 6, 7, 8
Methotrexate IT age adjusted dose intrathecal 1
Prophylactic drugs & Sterile Bowel
ƒ Sodamint 1 tab PO BID (<5yr) or TID (>5yr) First 2 weeks
ƒ Allopurinol (100 mg) 10 mg/kg/day divided BID-QID First 2 weeks
ƒ Clotrimazole troche (10 mg)
or nystatin suspension
1 tab PO TID (>5yr) or
nystatin 2 ml PO QID (<5yr) 1-28
drug <1 yr 1-2 yr 2-3 yr >3 yr
* age adjusted dose intrathecal chemotherapy Methotrexate 6 8 10 12
Ara-C 15 20 30 50
Patient’s name Age Sex
กุมภาพันธ์ 2549 แนวทางเวชปฏิบัติ : มะเร็งเม็ดเลือดขาวในเด็ก
28. 28
Hospital HN BW Ht BSA
Protocol TPOG-AML-01-05
Phase II CONSOLIDATION (8 weeks) Date started / /
week 1 2 3 4 5 6 7 8 9
day 1 8 15 22 29 36 43 50 57
Date given
Prednisolone ______________________
6-TG __________________________
Day 1-28
Day 1-56
Vincristine ______ mg IV push À À À À
Adriamycin ______ mg IV push ¿ ¿ ¿ ¿
Ara-C ___ mg in piggy back 100 ml IV drip I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
CTX ____ mg IV drip in 30 min „ „
Ara-C ______ mg IT* T T T T
Note ถ้าเมื่อใด febrile neutropenia ให้หยุดยาเคมีบำบัดของสัปดาห์นั้นไว้ก่อนจนกว่า ANC> 1,000-1,500 /uL
จึงให้ยาของสัปดาห์นั้นต่อไป
Drug Dosage Day
Prednisolone (5mg) 40 mg /m2 /day PO divided tid-qid 1-28 then taper off
6-thioguanine (6-TG 40 mg) 60 mg /m2 PO daily 1-56
Vincristine 1.5 mg /m2 IV weekly 1, 8, 15, 22
Adriamycin 30 mg /m2 IV weekly 1, 8, 15, 22
Cytosine Arabinoside (Ara-C) 75 mg/ m2 IV drip in 30 min, 4 days/wk x 8 wk week 1-8
Cyclophosphamide (CTX) 500 mg/m2 IV drip in 30 min with hydration 29, 57
Ara C intrathecal Age-adjusted dose* 35, 42, 49, 56
Co-trimoxazole 5 mg/kg/day divided BID Fri-Sat-Sun
Phase III CNS PROPHYLAXIS ** 4 weeks Date started / /
**Only for Patients with initial CNS involvement and age > 2 years only
Week 1 2 3 4
Date
6-TG ___________________ (60 mg/m2 day PO)
Cranial Irradiation _______ cGy x 10 fractions
MTX ___________ mg IT x 4 times T T T T
Date given
CSF examination: Gross appearance
Day 1-14
Pandy / Nonne / / / /
Benedict test
Cells (RBC / WBC) / / / /
Patient’s name Age Sex
Hospital HN BW Ht BSA
กุมภาพันธ์ 2549 แนวทางเวชปฏิบัติ : มะเร็งเม็ดเลือดขาวในเด็ก
29. 29
Protocol TPOG-AML-01-05
Phase IV MAINTENANCE PHASE (Total duration 2 years) Date Started ____/____/___
Give the following courses q 4 weeks
Drug Dosage Day
Course A (For month 1, 3, 5, 7)
Cytosine Arabinoside 40 mg/m2 /day IV x 4 days _____________________ Day 1-4
Adriamycin 25 mg/m2 IV push _____________________ Day 1
6-Thioguanine 60 mg/m2 /day PO _____________________ Daily
Co-trimoxazole 5 mg/m2 /day divided BID _____________________ Fri-Sat-Sun
Course B (For month 2, 4, 6, and 8 – 24 )
Cytosine Arabinoside 40 mg/m2 /day IV x 4 days _____________________ Day 1-4
6-Thioguanine 60 mg/m2 /day PO _____________________ Daily
Co-trimoxazole 5 mg/m2 /day divided BID _____________________ Fri-Sat-Sun
LP + Ara-C IT Age adjusted dose _____________________ q 2 months
BM aspiration * (Optional) q 4 months
BUN, creatinine, LFT q 4 months
Schedule:
Month 1 2 3 4 5 6 7 8
Date
Chemotherapy course: A B A B A B A B
BMA*, blood chem. „ „
LP+ Ara C____ mg IT ‹ ‹ ‹ ‹
Month 9 10 11 12 13 14 15 16
Date
Chemotherapy B B B B B B B B
BMA*, blood chem. „ „
LP+ Ara C____ mg IT ‹ ‹ ‹ ‹
Month 17 18 19 20 21 22 23 24
Date
Chemotherapy B B B B B B B B
BMA*, blood chem. „ „
LP+ Ara C____ mg IT ‹ ‹ ‹ ‹
END OF THERAPY Date / / _
กุมภาพันธ์ 2549 แนวทางเวชปฏิบัติ : มะเร็งเม็ดเลือดขาวในเด็ก
30. 30
Patient’s name Age Sex
Hospital HN BW Ht BSA
Protocol TPOG-AML-01-05
POST TREATMENT GUIDELINES
Guidelines for follow up patients post treatment
• 1st year : PE, CBC q 2 months.
• 2nd year : PE, CBC q 3 months.
• 3rd year : PE, CBC q 6 months
• After 3rd year : PE, CBC q 12 months
Bone marrow aspiration
1. Before discontinue chemotherapy
2. Unexplained cytopenia
3. Sign & symptom of relapse
Guideline for bactrim prophylaxis
1. Start when consolidation
2. Bactrim is given 5 mg of TMP /kg/day divided bid 2-3 times per week (M-W-F, F-Sa-Su, or Sa-Su)
3. Stop bactrim prophylaxis 1 week before and during CNS prophylaxis with high-dose methotrexate
Reimmunization
-post off treatment 1 yr.
Evaluation for long term side effects yearly
1. Growth chart
2. Learning problems
3. Endocrine evaluation and consultant when enter adolescent
4. Secondary malignancy
กุมภาพันธ์ 2549 แนวทางเวชปฏิบัติ : มะเร็งเม็ดเลือดขาวในเด็ก
31. 31
Appendix
Guideline for Administration of High dose Methotrexate > 1000 mg/m2
Modified Toxicity Criteria for Cancer Chemotherapy
Chemotherapy Modification Guideline for Hepatic Dysfunction
Chemotherapy Modification Guideline for Renal Dysfunction
Anthracyclin Record Sheet
Guideline For Drug Preparation
กุมภาพันธ์ 2549 แนวทางเวชปฏิบัติ : มะเร็งเม็ดเลือดขาวในเด็ก
32. 32
Guideline for Administration of High dose Methotrexate > 1000 mg/m2
1. ตรวจ CBC : ให้ยาได้ต่อเมื่อ WBC > 3000/μL, ANC > 1000/μL, Plt > 100,000/μL
2. ตรวจร่างกายไม่พบ mucositis หรือ oral ulcers
3. ตรวจ BUN, creatinine คำนวณ creatinine clearance, ปรับ dose ยาตาม creatinine clearance (Page 4)
4. หยุดยาต่อไปนี้ เนื่องจากจะเพิ่ม MTX toxicity
cotrimoxazole, salicylate, pyrimethamine, NSAIDs, penicillin, live virus vaccine, probenecid
5. Hydration and alkalinization
- ก่อนให้ยา high dose ต้องให้ hydration ด้วย 5%D in N/2 + NaHCO3 20-40 mEq/L + KCL
10mEq/L IV rate 125ml/m2/hr (2x maintenance rate) อย่างน้อย 2 ชม. เพื่อเพิ่ม urine output ให้ >
3 ml/kg/hr
- ก่อนเริ่มการ infusion ของยาควรตรวจให้ urine Sp. gr < 1.010 urine pH > 6.5 ก่อน
- ควรให้ fluid rate นี้ตลอดการให้ methotrexate และหลังจากยาหมด ควรให้ผู้ป่วยได้น้ำโดยการ
รับประทานรวมกับ IV fluid ไม่น้อยกว่า 125 ml/M2/hr (3000 ml/M2/day) อีกอย่างน้อย 24-48 ชม.
เพื่อให้มี urine output > 2 ml/kg/hr
6. Methotrexate administration (Total dose 1.5 gm/M2/24 hour)
ผสม Methotrexate 150 mg/M2 (10% of total dose) in 5%D N/2 100ml IV in 1 hour
ตามด้วย Methotrexate 1350 mg/M2 (90% of total dose) in 5%D N/2 500 ml IV drip in 23 hr
(หมายเหตุ – ลด rate IV ขณะ drip ยา โดยให้เป็น rate IV + chemo = 125 ml/M2/hr)
7. หากผู้ป่วยมี inadequate urine output > 3 hr หรือมี fluid overload สามารถให้ยาดังนี้
- Mannitol 200 mg/kg in NSS 25 ml IV over 15-60 min
- Furosemide 0.5-1 mg/kg IV push
8. Leucovorin rescue ให้เริ่ม leucovorin dose แรกหลังจากเริ่ม MTX 36 ชั่วโมงพอดี (หลัง MTX หมด 12
ชั่วโมง)โดยการกินหรือฉีดในขนาด 15 mg/M2q 6 hr x 6 doses หากคำนวณได้ยา < 15 mg ให้ยา 1 เม็ด (15
mg) โดยไม่ต้องแบ่งเม็ดยา หากคำนวณได้ยา > 15 mg ให้ยา 2 เม็ด
• หากเกิด mucositis หลังการให้ยา methotrexateครั้งที่แล้ว ให้เพิ่ม leucovorin rescue จากเดิมอีก
3 doses q 6 hr โดยไม่ลด dose ของ methotrexate
9. หลีกเลี่ยงการให้ยาที่มี nephrotoxicity อื่นๆในระยะเดียวกับที่ให้ยา methotrexate
กุมภาพันธ์ 2549 แนวทางเวชปฏิบัติ : มะเร็งเม็ดเลือดขาวในเด็ก
33. 33
Modified Toxicity Criteria for Cancer Chemotherapy
Site measure Toxicity grade WNL 0 Mild 1 Moderate 2 Severe 3 Unacceptable 4
WBC x 103/μL >4.0 3.0-3.9 2.0-2.9 1.0-1.9 <1.0
ANC x 103/μL >2.0 1.5-1.9 1.0-1.4 0.5-0.9 <0.5
hemorrhage none minimal Moderate Vital organs Life threatening
กุมภาพันธ์ 2549 แนวทางเวชปฏิบัติ : มะเร็งเม็ดเลือดขาวในเด็ก
Blood
thrombosis none Lab change peripheral Large vv. stroke
Infection fever <38oC 38-40 oC >40 oC, <72hr > 72 hr > 7 days Infection none mild moderate severe Life threatening
BUN <20 20-39 40-59 60-79 >80, uremia
Creatinine WNL <1.5 x N 1.5-2 x N 2-5 x N >5 x N
Cr. clearance WNL <1.5 x N 1.5-2 x N 2-5 x N >5 x N
Electrolytes WNL Mild, no S&S mild S&S Severe S&S Life threatening
Proteinuria neg 1+ 2+ - 3+ 4+ Nephrotic syn
Renal-bladder
Hematuria neg micro gross with clot massive
SGOT WNL <2.5 x N 2.6 - 5 x N 5.1 – 20 x N >20.0 x N
SGPT WNL <2.5 x N 2.6 - 5 x N 5.1 – 20 x N >20.0 x N
Alk phos WNL <2.5 x N 2.6 - 5 x N 5.1 – 20 x N >20.0 x N
Total bili WNL <1.5 x N 1.5 - 3 x N >3.0 x N
Liver
clinical precoma Hepatic coma
Amylase WNL <1.5 x N 1.5-2 x N 2-5 x N >5 x N
Pancreas Glucose (mg/dl) WNL 116-160 161-250 251-500 >500 U/S pancreas normal Sonolucency
(SL)
Localized SL,
↑size
Generalized
SL
Pseudo-cyst,
hemorrhagic
Nausea & vomit none mild ↓ intake Can’t eat Require TPN
Stomatitis none erythema, mild
soreness
Painful/edema
can eat
Cannot eat or
drink
Require TPN
Diarrhea none 2-3 /day 4-6 /day 7-10 /day > 10, bloody
Constipation none Mild ileus moderate severe > 96 hr
GI
Abdominal pain none mild moderate severe Need sedation
Peripheral none ↓ DTR mild
paresthesia,
constipation
severe pares-thesia
&
constipation
Severe
weakness
Paralysis, resp
Nervous dysfunction
system
CNS none Headache,
lethargy
Somnolence,
tremor, depress
confused, cord
dysfunction
Seizure, coma,
SIADH
Clinical normal tachypnea dyspnea O2 required Assist ventilator
pulmonary pAO2 > 90 80-89 65-79 50-64 <49
Vital capacity WNL 10-20%↓ 21-35%↓ 36-50%↓ >51%↓
EKG Normal ST-T change
sinus tachy
Atrial arrhyth,
unifocal PVC
Multifocal
PVC’s
cardiac Echo %FS Normal >30 24-30 20-24 <20
clinical normal Transient HT Persistent HT CHF mild Severe CHF,
cardiac temponard
Allergy none Rash, fever urticaria bronchospasm anaphylaxis
Objective No change 20-40db
loss<4kHz
>40 db loss
>4kHz
>40 db loss 2
kHz
>40 db loss <2
Hearing kHz Subjective No change Loss on
audiometry
Tinnitus, soft
speech
correctable c
hearing aid
deafness
Vision Normal Subtotal loss blindness
34. 34
Chemotherapy Modification Guideline for Hepatic Dysfunction
Criteria for Liver Toxicity
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
SGOT WNL < 2.5 x N 2.6 – 5 x N 5.1 – 20 x N > 20.0 x N
SGPT WNL < 2.5 x N 2.6 – 5 x N 5.1 – 20 x N > 20.0 x N
Alk phos WNL < 2.5 x N 2.6 – 5 x N 5.1 – 20 x N > 20.0 x N
Total bili WNL < 1.5 x N 1.5 – 3 x N > 3.0 x N
Clinical precoma hepatic coma
Modification of Drug with Liver Toxicity
Drug Grade 1 Grade 2 Grade 3 Grade 4
L-Asparaginase 100% 100% stop stop
6-MP, 6-TG 100% Restart 50% stop stop
Methotrexate 100% Restart 50% stop stop
BCNU, CCNU Restart 50% stop stop
Modification of Drug with liver-dependent metabolism
Bili (mg/dL) / SGOT (U/mL) < 1.5 / < 60 1.5 – 3.0 / 60 - 180 3.1 – 5.0 / > 180 > 5.0
Vincristine, Vinblastine 100% 50% stop stop
VP-16 100% 50% stop stop
Adriamycin, Idarubicin 100% 50% 25% stop
Actinomycin D 100% 50% 25% stop
Methotrexate 100% 50% 25% stop
Cyclophopshamide 100% 100% 25% stop
CCNU, BCNU 100% 100% 100% stop
5-FU 100% 100% 100% stop
Cytosine arabinoside 100% 100% 100% stop
DTIC, procarbazine 100% 100% 100% stop
กุมภาพันธ์ 2549 แนวทางเวชปฏิบัติ : มะเร็งเม็ดเลือดขาวในเด็ก
36. 36
Anthracyclin Record Sheet
Patient’s Name__________________________________Age_______Sex________
Diagnosis
Protocol
BW___________________Ht_________________BSA________________________
Anthracyclin used
Dose
Cumulative dose
กุมภาพันธ์ 2549 แนวทางเวชปฏิบัติ : มะเร็งเม็ดเลือดขาวในเด็ก
Date
mg Mg/m2 mg Mg/m2
EKG/Echo
37. Guideline For Drug Preparation 39
Classification Generic name Trade names Size Final preparation Stability Special consideration
Antibiotics Doxorubicin HCL Adriblastina®
Adriamycin
(ADR)
10mg
50mg
0.9%NSS 0.5mg/ml IV push
0.9%NSS 100ml IV drip
48hr at 4οC
24hr at room
temperature
Avoid sun exposure
Strong vesicant
Cardiotoxic
Echo when accumulative
dose >300mg/m2
Plant alkaloids Vincristine SO4
(VCR)
1mg 0.9%NSS to 1mg/10ml
7days at 4οC
Neurotoxic,Vesicant
Max dose 2 mg/day
Topoisomerase
inhibitors
Etoposide (VP-16) Vepesid®
Lastet
50mg
100mg
5%D/W ~ 0.6mg/ml IVdrip in 1hr
(ไม่ควรเกิน 1 mg/ml)
48 hr(0.4mg/ml)
8 hr (0.6 mg/ml)
2 hr (1 mg/ml)
Hypersensitivity
Record V/S q 15 mins.
Antimetabolites Methotrexate(MTX) Methotrexate
Abitrexate
50mg/5ml
50mg/2ml
<150 mg
+ 0.9%NSS 100 ml IV drip
>150 mg
+ 5%D NSS/2 500 ml IV drip
0.9%NSS to 2ml IT
48hr
Vigorously hydrate
for high dose
*See High dose MTX
protocol
Cytosine arabinoside
(ARA-C)
Cytosar®
Cytarine
100mg
500mg
0.9%NSS to 10ml IV push
0.9%NSS 100ml IV drip in 1-3 hr
5%D NSS/2 500ml Continuous
drip 24hr.
0.9%NSS to 8ml IT
48hr at 4οC
Alkylating
agents
Cyclophosphamide
(CTX)
Endoxan®
Alkyloxan
200mg
500mg
1000mg
0.9%NSS 10mg/ml IV drip
0.9%NSS 10mg/ml IV push
48hr at 4οC
6hr.at RT
Hemorrhagic cystitis
Vigorous hydration +
Mesna for high dose
protocol (>1g/m2)
Ifosfamide Holoxan® 500mg
1000mg
0.9%NSS 10mg/ml IV drip
24hr. at 4οC
Same as CTX
Miscellaneous Hydrocortisone 100mg 0.9%NSS to 5ml IT
Cacium Folinate Leucovorin
calcium
30mg
50mg
0.9%NSS to 10mg/ml IV push Start first dose at 6 hr after
stop MTX
Mesna Uromitexan® 400mg 5% D/W to 20ml IV drip in 15min 24hr at RT
L-asparaginase Leunase 10,000 U
5,000 U
Dilute with NSS to 2 ml IM 8 hr at 4οC
กุมภาพันธ์ 2549 แนวทางเวชปฎิบัติ : มะเร็งเม็ดเลือดขาว